Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver Sells 3,276 Shares

Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver sold 3,276 shares of Evolus stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the transaction, the chief financial officer now owns 148,502 shares of the company’s stock, valued at $2,224,559.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Evolus Stock Up 2.6 %

EOLS opened at $15.09 on Tuesday. The company has a debt-to-equity ratio of 6.26, a current ratio of 2.92 and a quick ratio of 2.67. The company’s 50-day moving average is $13.34 and its 200 day moving average is $12.99. Evolus, Inc. has a fifty-two week low of $7.44 and a fifty-two week high of $16.29. The firm has a market capitalization of $952.03 million, a P/E ratio of -14.37 and a beta of 1.30.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings data on Wednesday, July 31st. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The business had revenue of $66.91 million for the quarter, compared to analyst estimates of $65.06 million. Research analysts expect that Evolus, Inc. will post -0.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on EOLS. Cantor Fitzgerald reissued an “overweight” rating on shares of Evolus in a research report on Monday. Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Evolus in a research report on Thursday, August 1st. Finally, HC Wainwright reissued a “buy” rating and set a $27.00 price target on shares of Evolus in a research report on Thursday, August 1st.

Institutional Trading of Evolus

Several hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System raised its position in Evolus by 1.6% in the first quarter. California State Teachers Retirement System now owns 48,109 shares of the company’s stock worth $674,000 after acquiring an additional 739 shares during the period. ProShare Advisors LLC raised its position in Evolus by 9.9% in the first quarter. ProShare Advisors LLC now owns 11,542 shares of the company’s stock worth $162,000 after acquiring an additional 1,035 shares during the period. Arizona State Retirement System raised its position in Evolus by 9.4% in the second quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock worth $158,000 after acquiring an additional 1,253 shares during the period. Price T Rowe Associates Inc. MD raised its position in Evolus by 4.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 39,882 shares of the company’s stock worth $559,000 after acquiring an additional 1,637 shares during the period. Finally, Tradition Wealth Management LLC raised its position in Evolus by 44.8% in the fourth quarter. Tradition Wealth Management LLC now owns 8,000 shares of the company’s stock worth $84,000 after acquiring an additional 2,475 shares during the period. Institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.